Is it metastatic melanoma or is it sarcoidosis? Non-caseating granulomas due to pembrolizumab
Open Access
- 1 December 2020
- journal article
- editorial
- Published by BMJ in BMJ Case Reports
- Vol. 13 (12), e240701
- https://doi.org/10.1136/bcr-2020-240701
Abstract
This patient received adjuvant intensity-modulated radiotherapy, followed by intravenous pembrolizumab 200 mg every 21 days with a planned total duration of 1 year. He tolerated six cycles of pembrolizumab with only mild fatigue and cough. Follow-up PET/CT scan after these cycles revealed possible progression of his disease. There was fluorodeoxyglucose-avid adenopathy throughout the mediastinum, bilateral infraclavicular and supraclavicular nodes, and likely periaortic and porta hepatis nodes (figure 1).Keywords
This publication has 3 references indexed in Scilit:
- Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective StudyJournal of Clinical Medicine Research, 2019
- Sarcoidosis-Like Reactions Induced by Checkpoint InhibitorsJournal of Thoracic Oncology, 2018
- Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patientsJournal for ImmunoTherapy of Cancer, 2018